- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsing-remitting multiple sclerosis (RRMS)
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Natalizumab – March 2025
Natalizumab; Solution concentrate for I.V. infusion 300 mg in 15 mL; Tyruko®
Last updated
12 March 2025